To assess the effect of N-acetylcysteine (NAC) on acute renal failure and important clinical outcomes after cardiac surgery.
M4thode : Deux analystes ont r6alis6 des recherches de litt6ra-ture dans les bases de donn6es EMBASE et PubMed pour trouver des 6tudes randomis4es contr614es 6tudiant I'effet n6phroprotec-teur de la N-ac6tylcyst4ine en chirurgie cardiaque. Les effets th6ra-peutiques ont 4td calcul& en tant que risques relatifs (RR) avec des intervalles de confiance (IC) de 95 %. L'h~t6rog4n6it6 et le biais de publication ont 6t4 4valu& ~ I'aide du test 12 et de graphiques en entonnoir (,, funnel plots ,,), respectivement. Une m4ta-r6gression a 4t6 r6alis4e afin d'6valuer I'impact de la fonction r4nale de base et de I'utilisation d'aprotinine sur la fonction r6nale.

R~sultats : Sept 6tudes randomis6es contr(~14es (ERC) (n =
1000
Conclusion : Cette analyse n'a pas d~montr~ que le traitement avec la NAC a 4td associd ~ une protection rdnaie clinique pendant la chirurgie cardiaque, ni d'am61ioration dans les autres devenirs cliniques.
Kidney Failure and thoracic or cardiac surgery n=21 N-acetylcysteine and thoracic or cardiac surgery n=4 N-acetylcysteine and cardiopulmonary bypass n=13 N-acetylcysteine and kidney failure n=24 (all searches limited to human subjects and clinical trials) cute kidney injury (AKI) or renal impairment is an established complication of cardiac surgery occurring with an incidence p to 30%, depending on the definition. In recent years it has become obvious that postoperative renal dysfunction and failure does not merely represent an inconvenient complication prolonging intensive care treatment, infectious complications and hospitalization, but that AKI directly contributes to risk of mortality. 1~
Predisposing factors for the development of AKI after cardiac surgery are well documented and include advanced age, preoperative renal impairment, emergent/urgent or re-do surgery, complexity of the surgery, cardiopulmonary bypass duration, diabetes, congestive heart failure, left ventricular dysfunction, bleeding and blood product transfusion, preoperative use ofintra-aortic balloon pump and chronic obstructive pulmonary disease. 1,2,4-14 Pharmacological interventions to prevent AKI after cardiac surgery have been extensively investigated. To date, no agent has conferred renal protection.~5-39 Considerable interest has developed in the potential for Nacetylcysteine (NAC) to exert a renoprotective effect in patients undergoing cardiac surgery. Due to the beneficial effect of NAC on contrast nephropathy and its purported anti-inflammatory effects, several studies were undertaken to evaluate the renoprotective effects after cardiac surgery. 4°4s At this point, none of these studies has been able to demonstrate a significant benefit; although, taken individually, they were relatively small and underpowered to demonstrate an effect on the need for renal replacement therapy (RRT). Therefore, we conducted a systematic review and meta-analysis of the randomized controlled trials (RCTs) utilizing NAC in cardiac surgery requiring cardiopulmonary bypass, to determine the effect of NAC on AKI and on other important clinical outcomes.
Methods
This review adhered to the QUOROM recommendations. 46 Figure 1 .
Search strategy
Quality assessment and data abstraction
Two reviewers (F.N. and W.S.B.) performed quality assessment and data abstraction. Randomized controlled trial quality was rated with regard to randomization, allocation concealment, blinded outcome assessment, and dropouts. Data were abstracted on death, acute renal failure, RRT/dialysis, stroke, infarction, atrial fibrillation, red cell transfusion and reoperation. We accepted the outcome definitions used by the original researchers. A 25% increase from baseline serum creatinine was used as a surrogate measure of renal outcome by authors of all included studies. For the purpose of this meta-analysis and for consistency, we have adopted this surrogate measure in defining AKI. 
Analyses
We employed Review Manager 4.2.10 (Cochrane Collaboration) to combine treatment effects among studies with the same design. All analyses were performed on an intention-to-treat basis. Effects on dichotomous outcomes were expressed as relative risk (RR) with 95% confidence intervals (CI). Continuous outcomes were expressed as weighted mean differences with 95%"-CI. Heterogeneity was assessed with the I-statistic. In all analyses the random-effects model was used. Statistical significance was defined by a two-tailed P_< 0.05. For the purposes of this meta-anaiysis, the outcomes compared were increase in serum creatinine by 25% from baseline mortality, RRT, blood transfusion, reexploration, atrial fibrillation, myocardial infarction and stroke. For analysis the effects of baseline creatinine and dose of NAC on the outcomes we used metaregression? Meta-regression was performed using S-plus/R statistical software and the MiMe function. B Funnel-plots were used to assess for publication bias.
Results
The search strategy identified seven trials enrolling 1,000 patients. 4°-4s, 47 The details of the quality of the studies identified are outlined in Table I . All studies were RCTs, and analyzed on the basis of intention-totreat. Six of the seven trials were blinded. The design and characteristics of the studies are shown in Table II . There was variability in the NAC dosing regimens used across the seven trials, with the average dose received ranging from 100 mg to 1000 mg.hr -1. Inclusion criteria of all the studies except one, selected patients at moderate-to-high risk of developing postoperative renal injury. Other patient characteristics were similar across all studies. The pri-A Meta-regression is a tool which can be used to measure the variability of a given response. By assessing the effects of a covariate, (in this case both baseline creatinine and the dose of NAC) on the outcome of interest, (in this case the odds ratio of post operative renal failure), we can measure the extent that this covariate explains the heterogeneity. The r a has been used to measure the extent to which a covariate explains the hetero geneity. In this analysis we found a large degree of heterogeneity in the baseline crcatinine of the study populations and the dose of NAC used in the studies. mary study endpoint was the development of AKI in all but one of the studies. There was some variation in the definition and markers of AKI, but all studies reported a 25% increase in serum creatinine from baseline. Increase in serum creatinine by 25% is a surrogate measure o f renal failure. 48,49 Secondary outcome measures varied, but al] seven studies reported RRT and mortality. The studies varied with regard to the time period over which the change in renal function occurred, ranging from 72 hr 44,4s to five days postoperatively 40,41,43 Table III summarizes the results o f the meta-analysis. This analysis did not demonstrate any significant effects of NAC on outcomes. N-acetylcysteine was neither protective nor deleterious in its impact on an increase in serum creatinine by 25% from baseline (RR 0.80, 95%CI 0.62 to 1.05). There was no statistically significant difference between treatment and con-CANADIAN OURNAL OF ANESTHESIA trol groups in the requirement for RRT (RR 1.01, 95% CI 0.49 to 2.12), the prevalence of which was 2.8% .There was wide variance in baseline creatinine between studies. A meta-regression analysis shows no significant relationship between preoperative serum creatinine and postoperative change in creatinine ( Figure 3 ). However, there is a possibility that the beneficial effect of NAC is greater for patients with higher preoperative creatinine. This was not seen for RRT or for mortality. There is also a possibility that aprotinin use may counteract the beneficial effect of NAC ( Figure 2 ). When studies are divided by frequency of the use of aprotinin, studies in which nearly all patients received aprotinin had a RR of renal failure of 1.0, while the two studies where aprotinin was never used had a RR of 0.76 (95% CI .57-1.03). Inhospital death occurred in 14 of 503 patients receiving treatment with NAC and 18 of 497 control patients (RR 0.93, 95% CI, 0.41 to 2.07)• Four studies measured postoperative blood loss. There was a small, though significant increase in postoperative blood loss among patients treated with NAC (weighted mean difference 119 mL 95% CI 51, 187). There was no indication of publication bias (Figure 4) .
Discussion
This meta-analysis of seven well designed RCTs suggests that NAC does not confer renal protection in patients undergoing cardiac surgery. It has no significant impact on a 25% increase from baseline serum creatinine, which is a surrogate for acute renal failure necessitating RRT. The prevalence of RRT in these studies was 2.8%. Renal replacement therapy rates have previously been reported at 1.3-2.2% in derivation and validation cohorts, t° The relatively high RRT rate in these studies most likely reflects the inclusion of patients at moderate-to-high risk for developing AKI in the postoperative period. N-acetylcysteine was not associated with a reduction in RRT rates• In addition, other important clinical outcomes such as perioperative mortality, stroke, myocardial infarction and atrial fibrillation were not improved by treatment with NAC. Somewhat surprisingly, our analysis found that there was increased postoperative blood loss in patients receiving NAC. A possible mechanism for this effect may be related to a direct anti-aggregating effect on human platelets through an increased bioavailability of platelet nitric oxide. ~ N-acetylcysteine has also been found to potentiate the inhibition of platelet aggregation by nitroglycerin, s2
This analysis has several limitations. The meta-analyric tool is best used for hypothesis generation rather than hypothesis testing. Meta-analysis can be unreliable when multiple small studies, as seen in this analysis, are combined. Publication bias does not appear to be an issue in this study, as funnel plots show clearly that negative studies have been included (Figure 4 ). The quality of included trials is unlikely to have biased treatment effects since six studies were double-blinded, or evaluator-blinded. Allocation concealment was generally well described, abrogating the likelihood of increasing estimates of treatment benefit. Despite this meta-analysis, existing data still lack adequate power to conclusively determine whether NAC improves or worsens outcomes.
Meta-analysis is weakest and most controversial when studies disagree and there is heterogeneity. In our meta-analysis, the outcomes chosen for comparison are clinically important which is reflected in their repeated use by investigators of outcome after cardiac surgery. While our sample size is relatively small, there was little heterogeneity between the studies in terms of inclusion criteria or measured outcomes, although there is some variation in surrogate measures of outcome, definitions, and local practice guidelines. This analysis is further complicated by the issues surrounding perioperative blood loss and aprotinin. Aprotinin was administered in five of the seven studies analyzed, either routinely 42 or when the patient was deemed to be at high risk for bleeding 43,44 or in accordance with local institution policy in operation at the time. This analysis does not allow us to fully assess the effect that aprotinin may have had in these studies. Aprotinin use was moderate, being used in approximately 43% of the studied patients, and was equally distributed between groups of the two trials which universally used NAC. There was no effect of NAC on postoperative creatinine. However, in the two trials where no patients received aprotinin, NAC was associated with a smaller proportion of patients who had a postoperative rise in creatinine (RR 0.78 95% CI 0.59-1.08 P = 0.08). We can only speculate as to whether rates for renal failure, reoperation or transfusion were affected by the use of aprotinin, s3-s6 Finally, this meta-analysis cannot evaluate the interrelationship between preexisting renal dysfunction, the dosages of NAC, and the renal toxicity that may have been conferred with aprotinin. Heterogeneity in baseline creatinine and NAC dosages may account for the lack of significance in NAC effect. Further clarification on the effects of NAC might be provided by an individual patient data meta-analysis.
In conclusion, this analysis suggests there is no renal protection with NAC in cardiac surgery patients. However, we are unable to fully assess the effects of NAC dosage, the use of aprotinin, and baseline renal function and the interrelationship of these factors on outcomes. Future trials, if undertaken, could address this issue, if designed to include large numbers of patients with similar baseline renal function receiving the same dosing regimen of NAC. In the meantime, individual patient data meta-analysis within existing studies may provide answers.
